



26 June 2020

Sale of Ellex Lasers & Ultrasound Now Unconditional

Adelaide, Australia, 26 June 2020 – Ellex Medical Lasers Limited (ASX:ELX; OTCQX: ELXMY, ELXMF), a world leader in medical technologies for the diagnosis and treatment of eye disease, today provides an update on the conditions precedent following clearance from the Australian Competition and Consumer Commission on 11 June 2020 and the expected timetable for completion of the sale of Ellex Lasers & Ultrasound to Lumibird Group SA (**Lumibird**).

Ellex is pleased to report that all remaining conditions under the Share Sale and Purchase Agreement have now been satisfied and the transaction with Lumibird is now unconditional. Both parties expect the transaction will complete on 30 June 2020 as previously announced to the market.

A revised timetable for the transaction is shown below.

Indicative Timetable¹

Proposed date of Completion	30 June 2020
Announcement of effective date for the Capital Return on receipt of Class Ruling	Estimated 13 July 2020 ²
Effective date for the Capital Return	Estimated 14 July 2020 ²
Last day for trading in 'cum return of capital' shares	Estimated 15 July 2020 ²
Shares commence trading on an 'ex return of capital' basis	Estimated 16 July 2020 ²
Record Date for determining entitlement to participate in the Equal Capital Reduction	Estimated 17 July 2020 ²
Distribution Date for payment of capital returns and franked dividends to Shareholders	Estimated 24 July 2020 ²

Notes:

1 Dates are indicative only and subject to change.

2 Estimates only assuming receipt of the Class Ruling by 13 July 2020.

- ENDS -

This release dated 26 June 2020 has been authorised for lodgement to ASX by the Board of Directors of Ellex Medical Lasers Limited and lodged by Kimberley Menzies, Company Secretary.

ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative product that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex please contact:

Victor Previn
Executive Chairman
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes SA 5095
W +61 8 7074 8200
vprevin@ellex.com

Dr. Tom Duthy
Investor Relations & Corporate Development
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes SA 5095
M +61 402 493 727
tduthy@ellex.com